Improving heart failure medication use for patients with limited access in Denver
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
We will see if pharmacist-led medication visits plus simple education help adults with reduced-ejection-fraction heart failure who get care at Denver Health optimize their medications.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Denver Health and Hospital Authority Academic / other |
| Locations | 1 site (Denver, Colorado) |
| Trial ID | NCT07435662 on ClinicalTrials.gov |
What this trial studies
In this randomized, prospective trial at Denver Health, adults with heart failure and reduced ejection fraction are assigned to either pharmacist-directed medication adjustment visits with simplified patient education materials or to standard care. The intervention arm uses scheduled pharmacy follow-up visits focused on titrating guideline-directed heart failure medications and providing patient-centered education. Primary feasibility outcomes include the number of intervention visits completed and the proportion of visits that result in medication adjustments, with additional clinical and process measures collected. Key exclusions include severe renal failure or dialysis, cirrhosis, inability to consent, and non-English/non-Spanish speakers, and all participants must receive care within the Denver Health system.
Who should consider this trial
Good fit: Adults (≥18) with HFrEF (EF ≤40%) who receive care within the Denver Health system and can consent in English or Spanish are the ideal candidates.
Not a fit: Patients with eGFR <25 mL/min/1.73 m² or on dialysis, those with cirrhosis, those who cannot consent, non-English/non-Spanish speakers, or patients not receiving care at Denver Health are unlikely to benefit from participating.
Why it matters
Potential benefit: If successful, the approach could increase use of guideline-directed heart failure medications among underserved patients and potentially reduce hospitalizations and deaths.
How similar studies have performed: Prior programs using pharmacist-led titration and simplified education have improved medication optimization in privately insured groups, but this model has been less tested in limited-access, safety-net populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of HFrEF (EF ≤ 40%) * Receiving care within DHHA system Exclusion Criteria: * Estimated glomerular filtration rate (eGFR) \< 25 mL/min/1.73 m² or receiving dialysis. * Cirrhosis * Inability to consent * Non-English or non-Spanish speaking
Where this trial is running
Denver, Colorado
- Denver Health and Hospital Authority — Denver, Colorado, United States (Recruiting)
Study contacts
- Study coordinator: Ryan C Martin, MD, MPH
- Email: Ryan.Martin2@dhha.org
- Phone: 303-602-3899
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.